Asthma. Asthma, unspecified
Conditions
Interventions
Intervention 1: Eligible patients are randomly divided to two groups and the intervention group patients will be assigned to receive ciclesonide 80mg once daily with spacer via inhalation. These patie
Treatment - Drugs
Eligible patients are randomly divided to two groups and the intervention group patients will be assigned to receive ciclesonide 80mg once daily with spacer via inhalation. These patients will be educ
Eligible patients are randomly divided to two groups and the control group patients will be assigned to receive fluticasone 100 mg twice daily with spacer via inhalation. These patients will be educat
Sponsors
Massih Daneshvari hospital
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Ladies and gentlemen between 12 and 75 years as the definitive diagnosis of asthma is confirmed as mild persistent asthma: (Symptoms more than two days per week but less than daily incidence, symptoms at night more than two nights in month but less thatn every night, FEV1 = 80% predicted, FEV1 Variability% 20 -% 30 and the use of B2 agonists short acting more than two days a week but less than daily). Exclusion criteria: A) Having any of the criteria for moderate persistent asthma B) Pregnancy - Breastfeeding C) sensitivity to corticosteroids D) other lung diseases like COPD E) use of systemic corticosteroids in acute asthma attacks during two months before the run in period
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Forced expiratory volume in first second(FEV1). Timepoint: Before intervention and then 2,4, 8, 16 and 24 weeks after start of intervention. Method of measurement: Spirometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Forced vital capacity(FVC). Timepoint: Before intervention and at 2, 4, 8, 16 and 24 th week and in any time that the patient was referred due to adverse events. Method of measurement: Spirometry.;Number of asthma attacks. Timepoint: Any time it happened. Method of measurement: Recorded by patent himself/herself.;Total score of mini AQLQ questionare. Timepoint: Before intervention and at 2, 4, 8, 16 and 24 th week and in any time that the patient was referred due to adverse events. Method of measurement: Questionare will be completed by patients.;Nasopharyngitis as an adverse event. Timepoint: Before intervention and at 2, 4, 8, 16 and 24 th week and in any time that the patient was referred due to adverse events. Method of measurement: Physical examination and laboratory investigations if needed.;Any adverse effect due to drug consumption. Timepoint: Before intervention and at 2, 4, 8,16 and 24 th week and in any time that the patient was referred due to adverse events. Method of measurement: Physical examination and laboratory investigations if needed. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed